205 related articles for article (PubMed ID: 28202674)
1. LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker?
Taymans JM; Mutez E; Drouyer M; Sibran W; Chartier-Harlin MC
Biochem Soc Trans; 2017 Feb; 45(1):207-212. PubMed ID: 28202674
[TBL] [Abstract][Full Text] [Related]
2. Regulation of LRRK2 by Phosphatases.
Taymans JM
Adv Neurobiol; 2017; 14():145-160. PubMed ID: 28353283
[TBL] [Abstract][Full Text] [Related]
3. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers.
Wang S; Liu Z; Ye T; Mabrouk OS; Maltbie T; Aasly J; West AB
Acta Neuropathol Commun; 2017 Nov; 5(1):86. PubMed ID: 29166931
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
[TBL] [Abstract][Full Text] [Related]
6. Caught in the act: LRRK2 in exosomes.
Wang S; West AB
Biochem Soc Trans; 2019 Apr; 47(2):663-670. PubMed ID: 30837321
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner.
Kania E; Long JS; McEwan DG; Welkenhuyzen K; La Rovere R; Luyten T; Halpin J; Lobbestael E; Baekelandt V; Bultynck G; Ryan KM; Parys JB
Cell Death Dis; 2023 Jul; 14(7):436. PubMed ID: 37454104
[TBL] [Abstract][Full Text] [Related]
8. Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation.
Drouyer M; Bolliger MF; Lobbestael E; Van den Haute C; Emanuele M; Lefebvre R; Sibran W; De Wit T; Leghay C; Mutez E; Dzamko N; Halliday GM; Murayama S; Martoriati A; Cailliau K; Bodart JF; Chartier-Harlin MC; Baekelandt V; Nichols RJ; Taymans JM
Neurobiol Dis; 2021 Sep; 157():105426. PubMed ID: 34144124
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
[TBL] [Abstract][Full Text] [Related]
10. Cellular effects mediated by pathogenic LRRK2: homing in on Rab-mediated processes.
Madero-Pérez J; Fdez E; Fernández B; Lara Ordóñez AJ; Blanca Ramírez M; Romo Lozano M; Rivero-Ríos P; Hilfiker S
Biochem Soc Trans; 2017 Feb; 45(1):147-154. PubMed ID: 28202668
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 Phosphorylation: Behind the Scenes.
De Wit T; Baekelandt V; Lobbestael E
Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
[TBL] [Abstract][Full Text] [Related]
12. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S
Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855
[TBL] [Abstract][Full Text] [Related]
13. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
Chen J; Chen Y; Pu J
Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
[TBL] [Abstract][Full Text] [Related]
14. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
[TBL] [Abstract][Full Text] [Related]
15. Development of phospho-specific Rab protein antibodies to monitor
Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR
Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.
Gonzalez-Hunt CP; Thacker EA; Toste CM; Boularand S; Deprets S; Dubois L; Sanders LH
Sci Rep; 2020 Oct; 10(1):17293. PubMed ID: 33057100
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
[TBL] [Abstract][Full Text] [Related]
18. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
[TBL] [Abstract][Full Text] [Related]
19. The unconventional G-protein cycle of LRRK2 and Roco proteins.
Terheyden S; Nederveen-Schippers LM; Kortholt A
Biochem Soc Trans; 2016 Dec; 44(6):1611-1616. PubMed ID: 27913669
[TBL] [Abstract][Full Text] [Related]
20. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Padmanabhan S; Lanz TA; Gorman D; Wolfe M; Joyce A; Cabrera C; Lawrence-Henderson R; Levers N; Joshi N; Ma TC; Liong C; Narayan S; Alcalay RN; Hutten SJ; Baptista MAS; Merchant K
J Parkinsons Dis; 2020; 10(2):623-629. PubMed ID: 32007961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
